PDGF-C / SCDGF Protein Price Inquiry ( Available Sizes )
PDGF-C / SCDGF Protein Product Information
||A DNA sequence encoding the mature form of human PDGF-C (NP_057289.1) (Val 235- Gly 345 ) was fused with a polyhistidine tag at the C-terminus and a signal peptide at the N-terminus.
PDGF-C / SCDGF Protein QC Testing
||> 84 % as determined by SDS-PAGE
PDGF-C / SCDGF protein
||< 1.0 EU per μg of the protein as determined by the LAL method
||Samples are stable for up to twelve months from date of receipt at -70℃
|Predicted N terminal:
||The recombinant human PDGF-C consists of 121 amino acids and predicts a molecular mass of 13.8 kDa. It migrates as an approximately 20 KDa band in SDS-PAGE under reducing conditions.
||Lyophilized from sterile 20mM Tris, 500mM NaCl, pH 7.0, 10% gly.
- Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
- Please contact us for any concerns or special requirements.
PDGF-C / SCDGF Protein Usage Guide
||Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
||A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
PDGF-C / SCDGF Protein Related Products & Topics
PDGF-C / SCDGF Protein Description
The human platelet-derived growth factor C (PDGF-C) is one of the four member of the PDGF family of growth factors which are known mitogens and survival factors for cells of mesenchymal origin. They form four disulfide-linked homodimers (PDGF-AA, -BB, -CC, and -DD) and one heterodimer (PDGF-AB). PDGF-C has a unique two-domain structure consisting of an N-terminal CUB and a conserved C-terminal growth factor domain that are separated by a hinge region. PDGF-CC only binds to PDGF Rα with high affinity, activates the homodimerization of PDGF Rαβ, and induces the signal pathways, such as profibrotic pathways in hepatic fibrosis. PDGF-CC is involved in a variety of processes including angiogensis, morphogenesis and cardiovascular development, as well as the tumorigenesis. Meanwhile, recent studies have shown that the serine protease tissue plasminogen activator (tPA) used for treatment of acute stroke mediates the activation PDGF-CC, which suggests potential new strategies for cardiovascular and stroke treatment.
- Li X. et al., 2000, Nat Cell Biol. 2: 302-9.
- Gilbertson DG. et al., 2001, J Biol Chem. 276: 27406-14.
- Campbell JS. et al., 2005, Proc Natl Acad Sci. 102: 3389-94.
- Su EJ. et al., 2008, Nat Med. 14: 731-7.
- Zwerner JP. et al., 2001, Oncogene, 20: 626-33.